Tofacitib (i.e., tofacitibine citrate) can generally be combined with elamod for the treatment of rheumatoid arthritis, and the efficacy of the medication varies from person to person.
Tofacitib citrate may be used in combination with methotrexate or other non-bio-improving anti-rheumatic agents in adult patients with moderately to severely active rheumatoid arthritis in whom methotrexate is insufficiently effective or intolerant.
There are no clear contraindications to the use of the drug. The most common adverse reactions include upper respiratory tract infections, nasopharyngitis, and urinary tract infections. Take care to prevent and control infections during administration.
Elamod is a new antirheumatic drug indicated for the symptomatic treatment of active rheumatoid arthritis. Common adverse drug reactions include nausea, nausea (poor appetite), epigastric discomfort, elevated aminotransferases, rash, pruritus, and headache.
Contraindications to the use of the drug include hypersensitivity to the product, people with severe liver disease, people with previous or current peptic ulcers, pregnant women or women with the possibility of pregnancy. Liver function should be monitored during administration, and patients with active gastrointestinal disease should be monitored for black stools, abdominal pain, and other symptoms.
Both drugs can be used for the treatment of rheumatoid arthritis and do not have drug interactions, and Elamod does not belong to the use of tofacitibib citrate within the limitations of the improvement of the condition of the anti-rheumatic drugs or potent immunosuppressive drugs, so the two can be used in conjunction under the supervision of a physician.
Specific medication is recommended to consult a doctor, do not self-medication.